aspirin and Overweight

aspirin has been researched along with Overweight in 12 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.

Research

Studies (12)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Cumulative Radiation Exposure Within 90 Days

Cumulative radiation exposure from all cardiovascular diagnostic tests and procedures performed within 90 days after randomization. (NCT01174550)
Timeframe: 90 days

Percentage of Invasive Cardiac Catheterization Events Without Obstructive Coronary Artery Disease Within 90 Days Following Participant Randomization

Percentage of Invasive Cardiac Catheterization Events Without Obstructive Coronary Artery Disease (CAD)Within 90 Days Following Participant Randomization (NCT01174550)
Timeframe: Up to 90 days following participant randomization

Medical Cost

Assess and compare total medical cost for the two diagnostic testing arms by intention to treat at both 90 days and 3 years cumulative. (NCT01174550)
Timeframe: 90 days and 3 years cumulative

Quality of Life (QOL) as Measured by Complete Resolution of Symptoms That Led to the Initial Testing

Percentage of participants with improvement in Quality of Life as measured by complete resolution of the symptoms that led to initial testing (NCT01174550)
Timeframe: 6 month, 12 month 24 month

Quality of Life (QOL) as Measured by Duke Activity Status Index

Participant score in Quality of Life as measured by Duke Activity Status Index (DASI). DASI measures a person's functional capacity based on a 12-item questionnaire that correlates with peak O2 uptake during exercise testing. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). (NCT01174550)
Timeframe: Baseline, 6 months, 12 months 24 months

Quality of Life (QOL) as Measured by Seattle Angina Scale Anginal Frequency Subscale

Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 month, 12 month, 24 month

Quality of Life (QOL) as Measured by Seattle Anginal Quality of Life Subscale

Participant score Quality of Life measured by Seattle Angina Scale Anginal Frequency Subscale utilizing the Seattle Angina Questionnaire (SAQ). SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease: Anginal Stability: whether symptoms are changing. Anginal Frequency: how often patient having symptoms Physical Limitation: how much condition hampers ability to do what he wants.Treatment Satisfaction: how well patient understands care. Disease Perception: impact of condition on interpersonal relationships. Each dimension assigns response an value, beginning with 1 for response at the lowest level of functioning & summing across items within each of the 5 scales. Scale scores transformed to 0-100 range by subtracting the lowest scale. Higher score suggest symptoms more stable & less frequent, condition has less impact on activities, increased satisfaction with treatment, & perception of disease has less impact on interpersonal relationships. (NCT01174550)
Timeframe: Baseline, 6 months, 12 months, 24 months

Time to Death or Myocardial Infarction (MI)

Time to this secondary endpoint as defined as a composite of death and myocardial infarction (MI). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months

Time to Death, Myocardial Infarction (MI), Unstable Angina (UA), Complications, No Coronary Artery Disease (CAD)

Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, unstable angina hospitalization, and no coronary artery disease (CAD). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months

Time to Death, Myocardial Infarction (MI), Unstable Angina Hospitalization

Time to this secondary endpoint as defined as a composite of death, myocardial infarction (MI), and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months

Time to Major Complications From Cardiovascular (CV) Procedures

Time to this secondary endpoint as defined as a composite of major complications from cardiovascular procedures and testing (stroke, bleeding, anaphylaxis, renal failure). The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months

Time to Primary Endpoint

Time to primary endpoint as defined as a composite of death, myocardial infarction (MI), major complications from cardiovascular (CV) procedures or testing, and unstable angina hospitalization. The Kaplan-Meier events rates (cumulative percentage of participants with an event) were estimated for the anatomic and functional diagnostic test groups. (NCT01174550)
Timeframe: 90 days, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months

Reviews

1 review available for aspirin and Overweight

Trials

2 trials available for aspirin and Overweight

Other Studies

9 other studies available for aspirin and Overweight